{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T17:59:10Z","timestamp":1791568750876,"version":"4.3.4"},"reference-count":237,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2020,5,27]],"date-time":"2020-05-27T00:00:00Z","timestamp":1590537600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005202","name":"Muscular Dystrophy Association","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005202","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"DOI":"10.3389\/fimmu.2020.00776","type":"journal-article","created":{"date-parts":[[2020,5,27]],"date-time":"2020-05-27T04:39:44Z","timestamp":1590554384000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":153,"title":["Autoimmune Pathology in Myasthenia Gravis Disease Subtypes Is Governed by Divergent Mechanisms of Immunopathology"],"prefix":"10.3389","volume":"11","author":[{"given":"Miriam L.","family":"Fichtner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruoyi","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aoibh","family":"Bourke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard J.","family":"Nowak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin C.","family":"O\u2019Connor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2020,5,27]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1038\/nrneurol.2016.44","article-title":"Myasthenia gravis-autoantibody characteristics and their implications for therapy.","volume":"12","author":"Gilhus","year":"2016","journal-title":"Nat Rev Neurol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1038\/nri916","article-title":"Unravelling the pathogenesis of myasthenia gravis.","volume":"2","author":"Vincent","year":"2002","journal-title":"Nat Rev Immunol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"6717","DOI":"10.1046\/j.1432-1033.2000.01785.x","article-title":"Molecular targets for autoimmune and genetic disorders of neuromuscular transmission.","volume":"267","author":"Vincent","year":"2000","journal-title":"Eur J Biochem."},{"key":"B4","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1038\/85520","article-title":"Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies.","volume":"7","author":"Hoch","year":"2001","journal-title":"Nat Med."},{"key":"B5","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.jaut.2013.12.004","article-title":"A comprehensive analysis of the epidemiology and clinical characteristics of anti-LRP4 in myasthenia gravis.","volume":"52","author":"Zisimopoulou","year":"2014","journal-title":"J Autoimmun."},{"key":"B6","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1002\/ana.22312","article-title":"Autoantibodies to low-density lipoprotein receptor-related protein 4 in myasthenia gravis.","volume":"69","author":"Higuchi","year":"2011","journal-title":"Ann Neurol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1111\/joa.12034","article-title":"The role of muscle-specific tyrosine kinase (MuSK) and mystery of MuSK myasthenia gravis.","volume":"224","author":"Koneczny","year":"2013","journal-title":"J Anat."},{"key":"B8","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1001\/archneurol.2012.437","article-title":"Presence and pathogenic relevance of antibodies to clustered acetylcholine receptor in ocular and generalized myasthenia gravis.","volume":"69","author":"Jacob","year":"2012","journal-title":"Arch Neurol."},{"key":"B9","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1084\/jem.144.3.739","article-title":"Pathological mechanisms in experimental autoimmune myasthenia gravis. II. Passive transfer of experimental autoimmune myasthenia gravis in rats with anti-acetylcholine recepotr antibodies.","volume":"144","author":"Lindstrom","year":"1976","journal-title":"J Exp Med."},{"key":"B10","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1212\/WNL.31.3.282","article-title":"Myasthenia gravis: passive transfer to mice of antibody to human and mouse acetylcholine receptor.","volume":"31","author":"Oda","year":"1981","journal-title":"Neurology."},{"key":"B11","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1002\/mus.880090404","article-title":"Effector mechanisms in myasthenia gravis: end-plate function after passive transfer of IgG. Fab, and F(ab\u2019)2 hybrid molecules.","volume":"9","author":"Sterz","year":"1986","journal-title":"Muscle Nerve."},{"key":"B12","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1126\/science.1179220","article-title":"Myasthenia gravis: passive transfer from man to mouse.","volume":"190","author":"Toyka","year":"1975","journal-title":"Science"},{"key":"B13","article-title":"Maternal-fetal transmission of myasthenia gravis with acetylcholine-receptor antibody.","volume":"318","author":"Melber","year":"1988","journal-title":"N Engl J Med."},{"key":"B14","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1172\/JCI117369","article-title":"Association of neonatal myasthenia gravis with antibodies against the fetal acetylcholine receptor.","volume":"94","author":"Vernet-der Garabedian","year":"1994","journal-title":"J Clin Invest."},{"key":"B15","first-page":"222","article-title":"Antiacetylcholine receptor antibody in neonatal myasthenia gravis.","volume":"135","author":"Donaldson","year":"1981","journal-title":"Am J Dis Child."},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM197701062960125","article-title":"Anti-acetylcholine receptor antibody in neonatal myasthenia gravis.","volume":"296","author":"Keesey","year":"1977","journal-title":"N Engl J Med."},{"key":"B17","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1016\/j.nmd.2006.05.006","article-title":"A systematic review of diagnostic studies in myasthenia gravis.","volume":"16","author":"Benatar","year":"2006","journal-title":"Neuromus Dis."},{"key":"B18","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1016\/s0161-6420(99)00709-5","article-title":"An ice test for the diagnosis of myasthenia gravis.","volume":"106","author":"Golnik","year":"1999","journal-title":"Ophthalmology."},{"key":"B19","doi-asserted-by":"publisher","first-page":"e94263","DOI":"10.1172\/jci.insight.94263","article-title":"Autoantibody-producing plasmablasts after B cell depletion identified in muscle-specific kinase myasthenia gravis.","volume":"2","author":"Stathopoulos","year":"2017","journal-title":"JCI Insight."},{"key":"B20","first-page":"S17","article-title":"Lambert-Eaton myasthenic syndrome: electrophysiological evidence for a humoral factor.","volume":"5","author":"Newsom-Davis","year":"1982","journal-title":"Muscle Nerve."},{"key":"B21","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1016\/s1474-4422(14)70201-7","article-title":"Congenital myasthenic syndromes: pathogenesis, diagnosis, and treatment.","volume":"14","author":"Engel","year":"2015","journal-title":"Lancet Neurol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1093\/ejcts\/ezs663","article-title":"Thymoma and the increased risk of developing extrathymic malignancies: a multicentre study.","volume":"44","author":"Filosso","year":"2013","journal-title":"Eur J Cardio Thorac Surgery."},{"key":"B23","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1016\/S1474-4422(15)00145-3","article-title":"Myasthenia gravis: subgroup classification and therapeutic strategies.","volume":"14","author":"Gilhus","year":"2015","journal-title":"Lancet Neurol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.jaut.2014.01.003","article-title":"Diagnostic and clinical classification of autoimmune myasthenia gravis.","author":"Berrih-Aknin","year":"2014","journal-title":"J Autoimmun."},{"key":"B25","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1007\/BF00915728","article-title":"In vitro anti-acetylcholine receptor antibody synthesis by myasthenia gravis patient lymphocytes: correlations with thymic histology and thymic epithelial-cell interactions.","volume":"7","author":"Safar","year":"1987","journal-title":"J Clin Immunol."},{"key":"B26","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1056\/NEJM197505082921921","article-title":"Letter: B lymphocytes in the thymus of patients with myasthenia gravis.","volume":"292","author":"Staber","year":"1975","journal-title":"N Engl J Med."},{"key":"B27","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/s0165-5728(02)00038-3","article-title":"Thymic myoid cells and germinal center formation in myasthenia gravis; possible roles in pathogenesis.","volume":"125","author":"Roxanis","year":"2002","journal-title":"J Neuroimmunol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1016\/j.autrev.2013.03.007","article-title":"The different roles of the thymus in the pathogenesis of the various myasthenia gravis subtypes.","volume":"12","author":"Marx","year":"2013","journal-title":"Autoimmun Rev."},{"key":"B29","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.jaut.2013.12.011","article-title":"Myasthenia gravis: a comprehensive review of immune dysregulation and etiological mechanisms.","volume":"52","author":"Berrih-Aknin","year":"2014","journal-title":"J Autoimmun."},{"key":"B30","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1056\/NEJM197603252941303","article-title":"Detection of anti-acetylcholine receptor factors in serum and thymus from patients with myasthenia gravis.","volume":"294","author":"Mittag","year":"1976","journal-title":"N Engl J Med."},{"key":"B31","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.4049\/jimmunol.145.7.2115","article-title":"Thymic B cells from myasthenia gravis patients are activated B cells. Phenotypic and functional analysis.","volume":"145","author":"Leprince","year":"1990","journal-title":"J Immunol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.jneuroim.2008.06.027","article-title":"The myasthenia gravis thymus: a rare source of human autoantibody-secreting plasma cells for testing potential therapeutics.","author":"Hill","year":"2008","journal-title":"J Neuroimmunol."},{"key":"B33","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1212\/WNL.31.8.935","article-title":"Acetylcholine receptor antibody synthesis by thymic lymphocytes: correlation with thymic histology.","volume":"31","author":"Scadding","year":"1981","journal-title":"Neurology."},{"key":"B34","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/S0140-6736(78)90073-9","article-title":"In-vitro synthesis of anti-acetylcholine-receptor antibody by thymic lymphocytes in myasthenia gravis.","volume":"1","author":"Vincent","year":"1978","journal-title":"Lancet (London, England)."},{"key":"B35","first-page":"97","article-title":"Cell types required for anti-acetylcholine receptor antibody synthesis by cultured thymocytes and blood lymphocytes in myasthenia gravis.","volume":"58","author":"Willcox","year":"1984","journal-title":"Clin Exp Immunol."},{"key":"B36","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1056\/NEJM198111263052203","article-title":"Thymus cells in myasthenia gravis selectively enhance production of anti-acetylcholine-receptor antibody by autologous blood lymphocytes.","volume":"305","author":"Newsom-Davis","year":"1981","journal-title":"N Engl J Med."},{"key":"B37","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.4049\/jimmunol.137.4.1221","article-title":"Antibodies to acetylcholine receptor and tetanus toxoid: in vitro synthesis by thymic lymphocytes.","volume":"137","author":"Lisak","year":"1986","journal-title":"J Immunol."},{"key":"B38","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1212\/WNL.34.4.462","article-title":"Thymic B-cell activation in myasthenia gravis.","volume":"34","author":"Levinson","year":"1984","journal-title":"Neurology."},{"key":"B39","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1172\/JCI115843","article-title":"Transplantation of thymic autoimmune microenvironment to severe combined immunodeficiency mice. A new model of myasthenia gravis.","volume":"90","author":"Schonbeck","year":"1992","journal-title":"J Clin Invest."},{"key":"B40","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.jaut.2013.12.008","article-title":"Clonal heterogeneity of thymic B cells from early-onset myasthenia gravis patients with antibodies against the acetylcholine receptor.","volume":"52","author":"Vrolix","year":"2014","journal-title":"J Autoimmun."},{"key":"B41","doi-asserted-by":"publisher","first-page":"1935","DOI":"10.4049\/jimmunol.167.4.1935","article-title":"Somatic hypermutation and selection of B cells in thymic germinal centers responding to acetylcholine receptor in myasthenia gravis.","volume":"167","author":"Sims","year":"2001","journal-title":"J Immunol."},{"key":"B42","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1016\/0161-5890(95)00101-8","article-title":"Evidence for an antigen-driven selection process in human autoantibodies against acetylcholine receptor.","volume":"32","author":"Cardona","year":"1995","journal-title":"Mol Immunol."},{"key":"B43","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.4049\/jimmunol.158.4.1919","article-title":"Human anti-nicotinic acetylcholine receptor recombinant Fab fragments isolated from thymus-derived phage display libraries from myasthenia gravis patients reflect predominant specificities in serum and block the action of pathogenic serum antibodies.","volume":"158","author":"Graus","year":"1997","journal-title":"J Immunol."},{"key":"B44","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/0090-1229(85)90018-2","article-title":"Acetylcholine receptor antibody-producing cells in thymus and lymph nodes in myasthenia gravis.","volume":"34","author":"Fujii","year":"1985","journal-title":"Clin Immunol Immunopathol."},{"key":"B45","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1212\/WNL.35.4.577","article-title":"Acetylcholine receptor antibody production by bone marrow cells in a patient with myasthenia gravis.","volume":"35","author":"Fujii","year":"1985","journal-title":"Neurology."},{"key":"B46","doi-asserted-by":"crossref","first-page":"887","DOI":"10.4049\/jimmunol.136.3.887","article-title":"Specific activation of lymphocytes against acetylcholine receptor in the thymus in myasthenia gravis.","volume":"136","author":"Fujii","year":"1986","journal-title":"J Immunol."},{"key":"B47","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1111\/j.1749-6632.1981.tb33747.x","article-title":"Anti-acetylcholine receptor antibody synthesis by cultured lymphocytes in myasthenia gravis: thymic and peripheral blood cell interactions.","volume":"377","author":"Newsom-Davis","year":"1981","journal-title":"Ann N Y Acad Sci."},{"key":"B48","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1212\/wnl.33.5.604","article-title":"In vitro synthesis of antibodies to acetylcholine receptor by peripheral blood mononuclear cells of patients with myasthenia gravis.","volume":"33","author":"Lisak","year":"1983","journal-title":"Neurology."},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0185976","article-title":"Analysis of peripheral B cells and autoantibodies against the anti-nicotinic acetylcholine receptor derived from patients with myasthenia gravis using single-cell manipulation tools.","volume":"12","author":"Makino","year":"2017","journal-title":"PLoS One."},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-14350-8","article-title":"Characterization of an anti-fetal AChR monoclonal antibody isolated from a myasthenia gravis patient.","volume":"7","author":"Saxena","year":"2017","journal-title":"Sci Rep."},{"key":"B51","doi-asserted-by":"crossref","first-page":"2053","DOI":"10.1093\/clinchem\/39.10.2053","article-title":"Detection and characterization of blocking-type anti-acetylcholine receptor antibodies in sera from patients with myasthenia gravis.","volume":"39","author":"Hara","year":"1993","journal-title":"Clin Chem."},{"key":"B52","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1111\/j.1432-1033.1985.tb09054.x","article-title":"Monoclonal antibodies to Torpedo acetylcholine receptor. Characterisation of antigenic determinants within the cholinergic binding site.","volume":"150","author":"Whiting","year":"1985","journal-title":"Eur J Biochem."},{"key":"B53","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1126\/science.186.4158.55","article-title":"Serum globulin in myasthenia gravis: inhibition of alpha-bungarotoxin binding to acetylcholine receptors.","volume":"186","author":"Almon","year":"1974","journal-title":"Science"},{"key":"B54","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1056\/NEJM197805182982004","article-title":"Myasthenic antibodies cross-link acetylcholine receptors to accelerate degradation.","volume":"298","author":"Drachman","year":"1978","journal-title":"N Engl J Med."},{"key":"B55","doi-asserted-by":"publisher","first-page":"2449","DOI":"10.1002\/eji.1830220939","article-title":"Passive transfer of experimental myasthenia gravis via antigenic modulation of acetylcholine receptor.","volume":"22","author":"Loutrari","year":"1992","journal-title":"Eur J Immunol."},{"key":"B56","first-page":"82","article-title":"Acetylcholine receptor antibody in myasthenia gravis: predominance of IgG subclasses 1 and 3.","volume":"67","author":"Rodgaard","year":"1987","journal-title":"Clin Exp Immunol."},{"key":"B57","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1212\/WNL.43.6.1167","article-title":"Myasthenia gravis: quantitative immunocytochemical analysis of inflammatory cells and detection of complement membrane attack complex at the end-plate in 30 patients.","volume":"43","author":"Nakano","year":"1993","journal-title":"Neurology."},{"key":"B58","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/0165-5728(81)90015-1","article-title":"Binding properties and subclass distribution of anti-acetylcholine receptor antibodies in myasthenia gravis.","volume":"1","author":"Lefvert","year":"1981","journal-title":"J Neuroimmunol."},{"key":"B59","first-page":"267","article-title":"Immune complexes (IgG and C3) at the motor end-plate in myasthenia gravis: ultrastructural and light microscopic localization and electrophysiologic correlations.","volume":"52","author":"Engel","year":"1977","journal-title":"Mayo Clin Proc."},{"key":"B60","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1212\/wnl.29.2.179","article-title":"Passively transferred experimental autoimmune myasthenia gravis. Sequential and quantitative study of the motor end-plate fine structure and ultrastructural localization of immune complexes (IgG and C3), and of the acetylcholine receptor.","volume":"29","author":"Engel","year":"1979","journal-title":"Neurology."},{"key":"B61","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1002\/mus.26447","article-title":"Long-term safety and efficacy of eculizumab in generalized myasthenia gravis.","volume":"60","author":"Muppidi","year":"2019","journal-title":"Muscle Nerve."},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1212\/nxi.0000000000000104","article-title":"B lymphocytes in neuromyelitis optica.","volume":"2","author":"Bennett","year":"2015","journal-title":"Neurol Neuroimmunol Neuroinflamm."},{"key":"B63","doi-asserted-by":"publisher","first-page":"2000","DOI":"10.1172\/JCI122942","article-title":"Membrane assembly of aquaporin-4 autoantibodies regulates classical complement activation in neuromyelitis optica.","volume":"130","author":"Soltys","year":"2019","journal-title":"J Clin Invest."},{"key":"B64","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1002\/ana.20386","article-title":"Fewer thymic changes in MuSK antibody-positive than in MuSK antibody-negative MG.","volume":"57","author":"Leite","year":"2005","journal-title":"Ann Neurol."},{"key":"B65","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1212\/01.WNL.0000150587.71497.B6","article-title":"Thymus changes in anti-MuSK-positive and -negative myasthenia gravis.","volume":"64","author":"Lauriola","year":"2005","journal-title":"Neurology."},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000547","article-title":"MuSK myasthenia gravis monoclonal antibodies: Valency dictates pathogenicity.","volume":"6","author":"Huijbers","year":"2019","journal-title":"Neurol Neuroimmunol Neuroinflamm."},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.127167","article-title":"Characterization of pathogenic monoclonal autoantibodies derived from muscle-specific kinase myasthenia gravis patients.","volume":"4","author":"Takata","year":"2019","journal-title":"JCI Insight"},{"key":"B68","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.jneuroim.2008.01.013","article-title":"Clinical fluctuations in MuSK myasthenia gravis are related to antigen-specific IgG4 instead of IgG1.","volume":"195","author":"Niks","year":"2008","journal-title":"J Neuroimmunol."},{"key":"B69","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1016\/j.jaci.2012.08.037","article-title":"Tolerant beekeepers display venom-specific functional IgG4 antibodies in the absence of specific IgE.","volume":"131","author":"Varga","year":"2013","journal-title":"J Allergy Clin Immunol."},{"key":"B70","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1111\/j.1365-2222.1997.tb00727.x","article-title":"The natural history of Apis-specific IgG and IgG4 in beekeepers.","volume":"27","author":"Garcia-Robaina","year":"1997","journal-title":"Clin Exp Allergy."},{"key":"B71","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.1016\/j.bbadis.2017.07.038","article-title":"On the role of IgG4 in inflammatory conditions: lessons for IgG4-related disease.","volume":"1864","author":"Trampert","year":"2018","journal-title":"Biochim Biophys Acta Mol Basis Dis."},{"key":"B72","doi-asserted-by":"crossref","first-page":"3555","DOI":"10.4049\/jimmunol.160.7.3555","article-title":"IgE versus IgG4 production can be differentially regulated by IL-10.","volume":"160","author":"Jeannin","year":"1998","journal-title":"J Immunol."},{"key":"B73","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1016\/j.jaci.2013.01.014","article-title":"IgG4 production is confined to human IL-10-producing regulatory B cells that suppress antigen-specific immune responses.","volume":"131","author":"van de Veen","year":"2013","journal-title":"J Allergy Clin Immunol."},{"key":"B74","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1111\/j.1398-9995.2008.01774.x","article-title":"Distinct regulation of IgE, IgG4 and IgA by T regulatory cells and toll-like receptors.","volume":"63","author":"Meiler","year":"2008","journal-title":"Allergy."},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1155\/2016\/2196986","article-title":"Association between IgG4 autoantibody and complement abnormalities in systemic lupus erythematosus.","volume":"2016","author":"Pan","year":"2016","journal-title":"Mediators of inflammation."},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2019.107827","article-title":"Affinity-matured \u2018aquaporumab\u2019 anti-aquaporin-4 antibody for therapy of seropositive neuromyelitis optica spectrum disorders.","volume":"162","author":"Duan","year":"2020","journal-title":"Neuropharmacology."},{"key":"B77","doi-asserted-by":"publisher","first-page":"20783","DOI":"10.1073\/pnas.1313944110","article-title":"MuSK IgG4 autoantibodies cause myasthenia gravis by inhibiting binding between MuSK and Lrp4.","volume":"110","author":"Huijbers","year":"2013","journal-title":"Proc Natl Acad Sci USA."},{"key":"B78","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/s0923-1811(00)00158-4","article-title":"Predominant IgG4 subclass in autoantibodies of pemphigus vulgaris and foliaceus.","volume":"26","author":"Futei","year":"2001","journal-title":"J Dermatol Sci."},{"key":"B79","doi-asserted-by":"publisher","first-page":"2241","DOI":"10.1212\/WNL.0b013e31827689ad","article-title":"Neurofascin as a target for autoantibodies in peripheral neuropathies.","volume":"79","author":"Ng","year":"2012","journal-title":"Neurology."},{"key":"B80","first-page":"415","article-title":"Inhibition of complement activation by IgG4 antibodies.","volume":"64","author":"van der Zee","year":"1986","journal-title":"Clin Exp Immunol."},{"key":"B81","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1111\/cei.13024","article-title":"B cell phenotypes in patients with rheumatoid arthritis relapsing after rituximab: expression of B cell-activating factor-binding receptors on B cell subsets.","volume":"190","author":"Becerra","year":"2017","journal-title":"Clin Exp Immunol."},{"key":"B82","doi-asserted-by":"publisher","first-page":"p. 15","DOI":"10.1016\/C2009-0-00373-0","author":"Jefferis","year":"1990","journal-title":"Molecular Structure of Human IgG Subclasses. The Human IgG Subclasses."},{"key":"B83","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1016\/j.cbi.2016.04.019","article-title":"Roles of collagen Q in MuSK antibody-positive myasthenia gravis.","volume":"259","author":"Ohno","year":"2016","journal-title":"Chem Biol Interact."},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0080695","article-title":"MuSK myasthenia gravis IgG4 disrupts the interaction of LRP4 with MuSK but both IgG4 and IgG1-3 can disperse preformed agrin-independent AChR clusters.","volume":"8","author":"Koneczny","year":"2013","journal-title":"PLoS One."},{"key":"B85","doi-asserted-by":"publisher","first-page":"1554","DOI":"10.1126\/science.1144603","article-title":"Anti-inflammatory activity of human IgG4 antibodies by dynamic Fab arm exchange.","volume":"317","author":"van der Neut Kolfschoten","year":"2007","journal-title":"Science (New York, NY)."},{"key":"B86","doi-asserted-by":"publisher","first-page":"3238","DOI":"10.4049\/jimmunol.1003336","article-title":"Species-specific determinants in the IgG CH3 domain enable Fab-arm exchange by affecting the noncovalent CH3-CH3 interaction strength.","volume":"187","author":"Labrijn","year":"1950","journal-title":"J Immunol (Baltimore, Md"},{"key":"B87","doi-asserted-by":"publisher","first-page":"4002","DOI":"10.1002\/jps.24620","article-title":"Comprehensive analysis of the therapeutic IgG4 antibody pembrolizumab: hinge modification blocks half molecule exchange in vitro and in vivo.","volume":"104","author":"Yang","year":"2015","journal-title":"J Pharmac Sci."},{"key":"B88","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1046\/j.0019-2805.2001.01341.x","article-title":"IgG4 breaking the rules.","volume":"105","author":"Aalberse","year":"2002","journal-title":"Immunology."},{"key":"B89","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/0161-5890(93)90432-b","article-title":"A single amino acid substitution abolishes the heterogeneity of chimeric mouse\/human (IgG4) antibody.","volume":"30","author":"Angal","year":"1993","journal-title":"Mol Immunol."},{"key":"B90","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1002\/pro.5560060217","article-title":"Intrachain disulfide bond in the core hinge region of human IgG4.","volume":"6","author":"Bloom","year":"1997","journal-title":"Protein Sci."},{"key":"B91","doi-asserted-by":"publisher","first-page":"3488","DOI":"10.1016\/j.molimm.2009.07.009","article-title":"Comparison of the ability of wild type and stabilized human IgG(4) to undergo Fab arm exchange with endogenous IgG(4)in vitro and in vivo.","volume":"46","author":"Lewis","year":"2009","journal-title":"Mol Immunol."},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2014.00520","article-title":"IgG subclasses and allotypes: from structure to effector functions.","volume":"5","author":"Vidarsson","year":"2014","journal-title":"Front Immunol."},{"key":"B93","doi-asserted-by":"publisher","first-page":"4275","DOI":"10.4049\/jimmunol.0804338","article-title":"Human IgG4 binds to IgG4 and conformationally altered IgG1 via Fc-Fc interactions.","volume":"2009","author":"Rispens","year":"1950","journal-title":"J Immunol."},{"key":"B94","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/s0022-2836(02)00244-9","article-title":"Contrasting IgG structures reveal extreme asymmetry and flexibility.","volume":"319","author":"Saphire","year":"2002","journal-title":"J Mol Biol."},{"key":"B95","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.ab.2011.01.001","article-title":"Measurement of serum levels of natalizumab, an immunoglobulin G4 therapeutic monoclonal antibody.","volume":"411","author":"Rispens","year":"2011","journal-title":"Anal Biochem."},{"key":"B96","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1006\/jmbi.1994.0022","article-title":"Structure of an antibody-lysozyme complex unexpected effect of conservative mutation.","volume":"245","author":"Chacko","year":"1995","journal-title":"J Mol Biol."},{"key":"B97","doi-asserted-by":"publisher","first-page":"5710","DOI":"10.4049\/jimmunol.178.9.5710","article-title":"Identification of the site of human mannan-binding lectin involved in the interaction with its partner serine proteases: the essential role of Lys55.","volume":"2007","author":"Teillet","year":"1950","journal-title":"J Immunol."},{"key":"B98","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.1016\/j.str.2011.06.016","article-title":"Quantitative analysis of the interaction strength and dynamics of human IgG4 half molecules by native mass spectrometry.","volume":"2011","author":"Rose","year":"1993","journal-title":"Structure (London, England)."},{"key":"B99","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1111\/j.1365-2222.2009.03207.x","article-title":"Immunoglobulin G4: an odd antibody.","volume":"39","author":"Aalberse","year":"2009","journal-title":"Clin Exp Allergy."},{"key":"B100","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1046\/j.1365-2567.1999.00845.x","article-title":"Normal human immunoglobulin G4 is bispecific: it has two different antigen-combining sites.","volume":"97","author":"Schuurman","year":"1999","journal-title":"Immunology."},{"key":"B101","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1042\/bj2810317","article-title":"Expression, purification and characterization of a mouse-human chimeric antibody and chimeric Fab\u2019 fragment.","author":"King","year":"1992","journal-title":"Biochem J."},{"key":"B102","doi-asserted-by":"publisher","first-page":"10302","DOI":"10.1021\/ja203638y","article-title":"Mechanism of immunoglobulin G4 Fab-arm exchange.","volume":"133","author":"Rispens","year":"2011","journal-title":"J Am Chem Soc."},{"key":"B103","doi-asserted-by":"publisher","first-page":"5462","DOI":"10.1074\/jbc.M114.600973","article-title":"The S228P mutation prevents in vivo and in vitro IgG4 Fab-arm exchange as demonstrated using a combination of novel quantitative immunoassays and physiological matrix preparation.","volume":"290","author":"Silva","year":"2015","journal-title":"J Biol Chem."},{"key":"B104","doi-asserted-by":"publisher","first-page":"1719","DOI":"10.1084\/jem.165.6.1719","article-title":"Human autoantibodies against a desmosomal protein complex with a calcium-sensitive epitope are characteristic of pemphigus foliaceus patients.","volume":"165","author":"Eyre","year":"1987","journal-title":"J Exp Med."},{"key":"B105","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1083\/jcb.102.3.1109","article-title":"Further analysis of pemphigus autoantibodies and their use in studies on the heterogeneity, structure, and function of desmosomes.","volume":"102","author":"Jones","year":"1986","journal-title":"J Cell Biol."},{"key":"B106","doi-asserted-by":"publisher","first-page":"1714","DOI":"10.1001\/jama.264.13.1714","article-title":"Pemphigus. Skin failure mediated by autoantibodies.","volume":"264","author":"Stanley","year":"1990","journal-title":"JAMA."},{"key":"B107","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.1172\/jci114036","article-title":"Pemphigus and pemphigoid as paradigms of organ-specific, autoantibody-mediated diseases.","volume":"83","author":"Stanley","year":"1989","journal-title":"J Clin Investigat."},{"key":"B108","first-page":"1227","article-title":"A monoclonal antibody to the desmosomal glycoprotein desmoglein I binds the same polypeptide as human autoantibodies in pemphigus foliaceus.","volume":"1986","author":"Stanley","year":"1950","journal-title":"J Immunol."},{"key":"B109","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1016\/0092-8674(91)90360-b","article-title":"Autoantibodies against a novel epithelial cadherin in pemphigus vulgaris, a disease of cell adhesion.","volume":"67","author":"Amagai","year":"1991","journal-title":"Cell."},{"key":"B110","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1097\/00000372-198712000-00007","article-title":"Pemphigus foliaceus antibodies and a monoclonal antibody to desmoglein I demonstrate stratified squamous epithelial-specific epitopes of desmosomes.","volume":"9","author":"Rubinstein","year":"1987","journal-title":"Am J Dermatopathol."},{"key":"B111","author":"Sauvages","year":"1768","journal-title":"Nosologia Methodica Sistens Morborum Classes."},{"key":"B112","first-page":"521","article-title":"Chronic inflammatory demyelinating polyneuropathy.","volume":"7","author":"Rizzuto","year":"1985","journal-title":"Int J Tissue React."},{"key":"B113","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1002\/ana.23794","article-title":"Antibodies to contactin-1 in chronic inflammatory demyelinating polyneuropathy.","volume":"73","author":"Querol","year":"2013","journal-title":"Ann Neurol."},{"key":"B114","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1038\/nbt.1553","article-title":"Therapeutic IgG4 antibodies engage in Fab-arm exchange with endogenous human IgG4 in vivo.","volume":"27","author":"Labrijn","year":"2009","journal-title":"Nat Biotechnol."},{"key":"B115","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1002\/ana.21371","article-title":"Anti-MuSK patient antibodies disrupt the mouse neuromuscular junction.","volume":"63","author":"Cole","year":"2008","journal-title":"Ann Neurol."},{"key":"B116","doi-asserted-by":"publisher","first-page":"1536","DOI":"10.2353\/ajpath.2009.090040","article-title":"The effect of plasma from muscle-specific tyrosine kinase myasthenia patients on regenerating endplates.","volume":"175","author":"Ter Beek","year":"2009","journal-title":"Am J Pathol."},{"key":"B117","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.jaut.2016.11.005","article-title":"IgG4 autoantibodies against muscle-specific kinase undergo Fab-arm exchange in myasthenia gravis patients.","volume":"77","author":"Koneczny","year":"2017","journal-title":"J Autoimmun."},{"key":"B118","doi-asserted-by":"publisher","DOI":"10.1101\/2020.03.14.988758","article-title":"Self-antigen driven affinity maturation is required for pathogenic monovalent IgG4 autoantibody development.","author":"Fichtner","year":"2020","journal-title":"bioRxiv."},{"key":"B119","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1172\/jci114426","article-title":"Monovalent Fab\u2019 immunoglobulin fragments from endemic pemphigus foliaceus autoantibodies reproduce the human disease in neonatal Balb\/c mice.","volume":"85","author":"Rock","year":"1990","journal-title":"J Clin Invest."},{"key":"B120","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1172\/JCI24185","article-title":"Genetic and functional characterization of human pemphigus vulgaris monoclonal autoantibodies isolated by phage display.","volume":"115","author":"Payne","year":"2005","journal-title":"J Clin Invest."},{"key":"B121","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1038\/sj.jid.5701132","article-title":"Isolation of pathogenic monoclonal anti-desmoglein 1 human antibodies by phage display of pemphigus foliaceus autoantibodies.","volume":"128","author":"Ishii","year":"2008","journal-title":"J Invest Dermatol."},{"key":"B122","doi-asserted-by":"publisher","first-page":"5615","DOI":"10.4049\/jimmunol.0901691","article-title":"Antibodies to the desmoglein 1 precursor proprotein but not to the mature cell surface protein cloned from individuals without pemphigus.","volume":"183","author":"Yamagami","year":"2009","journal-title":"J Immunol."},{"key":"B123","doi-asserted-by":"publisher","DOI":"10.12688\/f1000research.9476.1","article-title":"Rituximab therapy in pemphigus and other autoantibody-mediated diseases.","volume":"6","author":"Ran","year":"2017","journal-title":"F1000Res."},{"key":"B124","doi-asserted-by":"publisher","DOI":"10.1212\/nxi.0000000000000149","article-title":"Rituximab in treatment-resistant CIDP with antibodies against paranodal proteins.","volume":"2","author":"Querol","year":"2015","journal-title":"Neurol Neuroimmunol Neuroinflam."},{"key":"B125","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1212\/WNL.0b013e3182407982","article-title":"Long-lasting treatment effect of rituximab in MuSK myasthenia.","volume":"78","author":"Diaz-Manera","year":"2012","journal-title":"Neurology."},{"key":"B126","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3005166","article-title":"Long-term remissions of severe pemphigus after rituximab therapy are associated with prolonged failure of desmoglein B cell response.","volume":"5","author":"Colliou","year":"2013","journal-title":"Sci Transl Med."},{"key":"B127","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1007\/s00415-011-6194-7","article-title":"Anti-LRP4 autoantibodies in AChR- and MuSK-antibody-negative myasthenia gravis.","volume":"259","author":"Pevzner","year":"2012","journal-title":"J Neurol."},{"key":"B128","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1001\/archneurol.2011.2393","article-title":"Autoantibodies to lipoprotein-related protein 4 in patients with double-seronegative myasthenia gravis.","volume":"69","author":"Zhang","year":"2012","journal-title":"Arch Neurol."},{"key":"B129","doi-asserted-by":"publisher","first-page":"2210","DOI":"10.4049\/jimmunol.1801295","article-title":"Autoantibodies against neurologic antigens in nonneurologic autoimmunity.","volume":"202","author":"Stathopoulos","year":"2019","journal-title":"J Immunol."},{"key":"B130","doi-asserted-by":"publisher","DOI":"10.1186\/s12883-016-0758-1","article-title":"Myasthenic symptoms in anti-low-density lipoprotein receptor-related protein 4 antibody-seropositive amyotrophic lateral sclerosis: two case reports.","volume":"16","author":"Takahashi","year":"2016","journal-title":"BMC Neurol."},{"key":"B131","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1002\/acn3.26","article-title":"LRP4 antibodies in serum and CSF from amyotrophic lateral sclerosis patients.","volume":"1","author":"Tzartos","year":"2014","journal-title":"Ann Clin Transl Neurol."},{"key":"B132","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.autrev.2018.07.011","article-title":"Characterization of the thymus in Lrp4 myasthenia gravis: Four cases.","volume":"18","author":"Koneczny","year":"2019","journal-title":"Autoimmun Rev."},{"key":"B133","doi-asserted-by":"publisher","first-page":"212","DOI":"10.3389\/fimmu.2020.00212","article-title":"Autoantibody specificities in myasthenia gravis; implications for improved diagnostics and therapeutics.","volume":"11","author":"Lazaridis","year":"2020","journal-title":"Front Immunol."},{"key":"B134","doi-asserted-by":"publisher","first-page":"1312","DOI":"10.1007\/s00415-011-6344-y","article-title":"Anti-voltage-gated potassium channel Kv1.4 antibodies in myasthenia gravis.","volume":"259","author":"Romi","year":"2012","journal-title":"J Neurol."},{"key":"B135","doi-asserted-by":"publisher","first-page":"1976","DOI":"10.1212\/WNL.0000000000000478","article-title":"Anti-agrin autoantibodies in myasthenia gravis.","volume":"82","author":"Gasperi","year":"2014","journal-title":"Neurology."},{"key":"B136","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1016\/j.autrev.2014.08.039","article-title":"Cortactin autoantibodies in myasthenia gravis.","volume":"13","author":"Gallardo","year":"2014","journal-title":"Autoimmun Rev."},{"key":"B137","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/j.jns.2014.12.015","article-title":"Collagen Q\u2013a potential target for autoantibodies in myasthenia gravis.","volume":"348","author":"Zoltowska Katarzyna","year":"2015","journal-title":"J Neurol Sci."},{"key":"B138","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0091816","article-title":"Autoantibodies to agrin in myasthenia gravis patients.","volume":"9","author":"Zhang","year":"2014","journal-title":"PLoS One."},{"key":"B139","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1111\/j.1600-0404.2006.00608.x","article-title":"Titin and ryanodine receptor antibodies in myasthenia gravis.","volume":"183","author":"Skeie","year":"2006","journal-title":"Acta Neurol Scand Suppl."},{"key":"B140","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1111\/j.1365-2249.1990.tb05440.x","article-title":"Patients with myasthenia gravis and thymoma have in their sera IgG autoantibodies against titin.","volume":"82","author":"Aarli","year":"1990","journal-title":"Clin Exp Immunol."},{"key":"B141","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1002\/ana.410320419","article-title":"Ryanodine receptor autoantibodies in myasthenia gravis patients with a thymoma.","volume":"32","author":"Mygland","year":"1992","journal-title":"Ann Neurol."},{"key":"B142","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1084\/jem.164.4.1043","article-title":"Thymic B lymphocyte clones from patients with myasthenia gravis secrete monoclonal striational autoantibodies reacting with myosin, alpha actinin, or actin.","volume":"164","author":"Williams","year":"1986","journal-title":"J Exp Med."},{"key":"B143","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1212\/01.wnl.0000254620.45529.97","article-title":"Clinical comparison of anti-MuSK- vs anti-AChR-positive and seronegative myasthenia gravis.","volume":"68","author":"Deymeer","year":"2007","journal-title":"Neurology."},{"key":"B144","doi-asserted-by":"publisher","first-page":"2304","DOI":"10.1093\/brain\/awg223","article-title":"Clinical correlates with anti-MuSK antibodies in generalized seronegative myasthenia gravis.","volume":"126","author":"Evoli","year":"2003","journal-title":"Brain."},{"key":"B145","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1111\/j.1600-0404.2006.00733.x","article-title":"The effectiveness of thymectomy on seronegative generalized myasthenia gravis: comparing with seropositive cases.","volume":"115","author":"Yuan","year":"2007","journal-title":"Acta Neurol Scand."},{"key":"B146","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1034\/j.1600-0404.2003.00209.x","article-title":"Response of thymectomy: clinical and pathological characteristics among seronegative and seropositive myasthenia gravis patients.","volume":"109","author":"Guillermo","year":"2004","journal-title":"Acta Neurol Scand."},{"key":"B147","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1212\/wnl.38.4.514","article-title":"Seronegative myasthenia gravis.","volume":"38","author":"Soliven","year":"1988","journal-title":"Neurology."},{"key":"B148","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1111\/j.1468-1331.2005.01137.x","article-title":"Seronegative myasthenia gravis: disease severity and prognosis.","volume":"12","author":"Romi","year":"2005","journal-title":"Eur J Neurol."},{"key":"B149","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1111\/nyas.13537","article-title":"Developing treatment guidelines for myasthenia gravis.","volume":"1412","author":"Sanders","year":"2018","journal-title":"Ann N Y Acad Sci."},{"key":"B150","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD006986.pub3","article-title":"Acetylcholinesterase inhibitor treatment for myasthenia gravis.","author":"Mehndiratta","year":"2014","journal-title":"Cochr Datab Syst Rev."},{"key":"B151","first-page":"1198","article-title":"Treatment of myasthenia gravis with physostigmine.","volume":"2","author":"Walker","year":"1934","journal-title":"Lancet"},{"key":"B152","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1212\/wnl.23.12.1273","article-title":"Study of long-term anticholinesterase therapy. Effects on neuromuscular transmission and on motor end-plate fine structure.","volume":"23","author":"Engel","year":"1973","journal-title":"Neurology."},{"key":"B153","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1177\/1756285608093888","article-title":"Progress in the treatment of myasthenia gravis.","volume":"1","author":"Gold","year":"2008","journal-title":"Ther Adv Neurol Dis."},{"key":"B154","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1097\/00000658-193910000-00005","article-title":"Myasthenia gravis and tumors of the thymic region: report of a case in which the tumor was removed.","volume":"110","author":"Blalock","year":"1939","journal-title":"Ann Surg."},{"key":"B155","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1001\/archneurpsyc.1949.02310110002001","article-title":"Thymectomy in treatment of myasthenia gravis; report based on 32 cases.","volume":"61","author":"Eaton","year":"1949","journal-title":"Arch Neurol Psychiatry."},{"key":"B156","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1056\/NEJMoa1602489","article-title":"Randomized trial of thymectomy in myasthenia gravis.","volume":"375","author":"Wolfe","year":"2016","journal-title":"N Engl J Med."},{"key":"B157","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/S1474-4422(18)30392-2","article-title":"Long-term effect of thymectomy plus prednisone versus prednisone alone in patients with non-thymomatous myasthenia gravis: 2-year extension of the MGTX randomised trial.","volume":"18","author":"Wolfe","year":"2019","journal-title":"Lancet Neurol."},{"key":"B158","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1111\/nyas.13519","article-title":"Thymus involvement in early-onset myasthenia gravis.","volume":"1412","author":"Cron","year":"2018","journal-title":"Ann N Y Acad Sci."},{"key":"B159","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1111\/j.1749-6632.1987.tb51282.x","article-title":"The role of the thymus in myasthenia gravis: immunohistological and immunological studies in 115 cases.","volume":"505","author":"Berrih-Aknin","year":"1987","journal-title":"Ann N Y Acad Sci."},{"key":"B160","doi-asserted-by":"publisher","first-page":"1276","DOI":"10.1212\/WNL.33.10.1276","article-title":"Acetylcholine receptor antibody and clinical response to thymectomy in myasthenia gravis.","volume":"33","author":"Vincent","year":"1983","journal-title":"Neurology."},{"key":"B161","doi-asserted-by":"publisher","first-page":"1922","DOI":"10.1016\/S0022","article-title":"The immunologic role of thymectomy in the treatment of myasthenia gravis: implication of thymus-associated B-lymphocyte subset in reduction of the anti-acetylcholine receptor antibody titer.","volume":"126","author":"Okumura","year":"2003","journal-title":"J Thorac Cardiovasc Surg."},{"key":"B162","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1002\/mus.26300","article-title":"Factors predicting remission in thymectomized patients with acetylcholine receptor antibody-positive myasthenia gravis.","volume":"58","author":"Kim","year":"2018","journal-title":"Muscle Nerve."},{"key":"B163","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1053\/j.semtcvs.2016.04.002","article-title":"Thymectomy for myasthenia gravis : complete stable remission and associated prognostic factors in over 1000 Cases.","volume":"28","author":"Kaufman","year":"2016","journal-title":"Sem Thor Cardiovas Surgery."},{"key":"B164","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1111\/ane.12289","article-title":"Eight-year follow-up of patients with myasthenia gravis after thymectomy.","volume":"131","author":"Yu","year":"2015","journal-title":"Acta Neurol Scand."},{"key":"B165","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1212\/wnl.32.1.83","article-title":"Reoperation after transcervical thymectomy for myasthenia gravis.","volume":"32","author":"Masaoka","year":"1982","journal-title":"Neurology."},{"key":"B166","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1212\/wnl.41.6.923","article-title":"Repeat thymectomy in chronic refractory myasthenia gravis.","volume":"41","author":"Miller","year":"1991","journal-title":"Neurology."},{"key":"B167","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1001\/jamaneurol.2016.4190","article-title":"Durability of the rituximab response in acetylcholine receptor autoantibody-positive myasthenia gravis.","volume":"74","author":"Robeson","year":"2016","journal-title":"JAMA Neurol."},{"key":"B168","doi-asserted-by":"publisher","first-page":"1352","DOI":"10.1016\/S0140-6736(19)31817-3","article-title":"Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2\/3 trial.","volume":"394","author":"Cree","year":"2019","journal-title":"Lancet (London, England)."},{"key":"B169","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.jaut.2013.12.015","article-title":"Both Treg cells and Tconv cells are defective in the Myasthenia gravis thymus: roles of IL-17 and TNF-alpha.","volume":"52","author":"Gradolatto","year":"2014","journal-title":"J Autoimmun."},{"key":"B170","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/j.ejcts.2009.02.021","article-title":"Long-term outcome of thoracoscopic extended thymectomy for nonthymomatous myasthenia gravis.","volume":"36","author":"Pompeo","year":"2009","journal-title":"Eur J Cardio Thor surgery."},{"key":"B171","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1002\/mus.26404","article-title":"Thymectomy may not be associated with clinical improvement in MuSK myasthenia gravis.","volume":"59","author":"Clifford","year":"2019","journal-title":"Muscle Nerve."},{"key":"B172","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1038\/nrneurol.2012.203","article-title":"B cells and antibodies in multiple sclerosis pathogenesis and therapy.","volume":"8","author":"Krumbholz","year":"2012","journal-title":"Nat Rev Neurol."},{"key":"B173","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1002\/ajh.20169","article-title":"Response of myasthenia gravis to rituximab in a patient with non-Hodgkin lymphoma.","volume":"77","author":"Gajra","year":"2004","journal-title":"Am J Hematol."},{"key":"B174","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1177\/1756285611411503","article-title":"Response of patients with refractory myasthenia gravis to rituximab: a retrospective study.","volume":"4","author":"Nowak","year":"2011","journal-title":"Ther Adv Neurol Dis."},{"key":"B175","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1136\/jnnp-2012-303664","article-title":"Long-term benefit of rituximab in MuSK autoantibody myasthenia gravis patients.","volume":"84","author":"Keung","year":"2013","journal-title":"J Neurol Neurosurg Psychiatry."},{"key":"B176","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1002\/acn3.564","article-title":"The impact of rituximab infusion protocol on the long-term outcome in anti-MuSK myasthenia gravis.","volume":"5","author":"Cortes-Vicente","year":"2018","journal-title":"Ann Clin Transl Neurol."},{"key":"B177","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.1212\/wnl.33.10.1316","article-title":"Myasthenia gravis: long-term correlation of binding and bungarotoxin blocking antibodies against acetylcholine receptors with changes in disease severity.","volume":"33","author":"Besinger","year":"1983","journal-title":"Neurology."},{"key":"B178","article-title":"B cell targeted treatment in myasthenia gravis A phase 2 trial of rituximab in MG: topline results.","author":"Nowak","year":"2018","journal-title":"Papper Presended at the 70th American Academy of Neurology Annual Meeting."},{"key":"B179","doi-asserted-by":"publisher","first-page":"4653","DOI":"10.1182\/blood-2007-11-123844","article-title":"The human spleen is a major reservoir for long-lived vaccinia virus-specific memory B cells.","volume":"111","author":"Mamani-Matsuda","year":"2008","journal-title":"Blood."},{"key":"B180","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1002\/art.21617","article-title":"Reconstitution of peripheral blood B cells after depletion with rituximab in patients with rheumatoid arthritis.","volume":"54","author":"Leandro","year":"2006","journal-title":"Arthr Rheumatism."},{"key":"B181","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.clim.2006.08.009","article-title":"B cell reconstitution after rituximab treatment of lymphoma recapitulates B cell ontogeny.","volume":"122","author":"Anolik","year":"2007","journal-title":"Clin Immunol (Orlando, Fla)."},{"key":"B182","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1093\/rheumatology\/key428","article-title":"Effect of rituximab treatment on T and B cell subsets in lymph node biopsies of patients with rheumatoid arthritis.","volume":"58","author":"Ramwadhdoebe","year":"2019","journal-title":"Rheumatology (Oxford, England)."},{"key":"B183","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1001\/archderm.143.8.1033","article-title":"Treatment of severe pemphigus with rituximab: report of 12 cases and a review of the literature.","volume":"143","author":"Cianchini","year":"2007","journal-title":"Arch Dermatol."},{"key":"B184","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.4049\/jimmunol.1501843","article-title":"Distinctions among circulating antibody-secreting cell populations, including B-1 cells, in human adult peripheral blood.","volume":"196","author":"Quach","year":"2016","journal-title":"J Immunol."},{"key":"B185","doi-asserted-by":"publisher","DOI":"10.1101\/840389","article-title":"Single-cell immune repertoire tracing identifies rituximab refractory B cells that emerge during relapse.","author":"Jiang","year":"2019","journal-title":"bioRxiv."},{"key":"B186","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.00613","article-title":"Long lasting rituximab-induced reduction of specific - but not of total- IgG4 in MuSK-positive myasthenia gravis.","author":"Marino","year":"2020","journal-title":"Front Immunol."},{"key":"B187","doi-asserted-by":"publisher","DOI":"10.1177\/1756286418761697","article-title":"B cell-based therapies in CNS autoimmunity: differentiating CD19 and CD20 as therapeutic targets.","volume":"11","author":"Forsthuber","year":"2018","journal-title":"Ther Adv Neurol Dis."},{"key":"B188","doi-asserted-by":"publisher","first-page":"4823","DOI":"10.4049\/jimmunol.1401478","article-title":"Single dose of glycoengineered anti-CD19 antibody (MEDI551) disrupts experimental autoimmune encephalomyelitis by inhibiting pathogenic adaptive immune responses in the bone marrow and spinal cord while preserving peripheral regulatory mechanisms.","volume":"2014","author":"Chen","year":"1950","journal-title":"J Immunol."},{"key":"B189","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.4049\/jimmunol.1501376","article-title":"Autoreactive CD19+CD20- plasma cells contribute to disease severity of experimental autoimmune encephalomyelitis.","volume":"2016","author":"Chen","year":"1950","journal-title":"J Immunol."},{"key":"B190","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1177\/1352458517740641","article-title":"Safety and tolerability of inebilizumab (MEDI-551), an anti-CD19 monoclonal antibody, in patients with relapsing forms of multiple sclerosis: Results from a phase 1 randomised, placebo-controlled, escalating intravenous and subcutaneous dose study.","volume":"25","author":"Agius","year":"2019","journal-title":"Mul Scl (Houndmills Basingstoke England)."},{"key":"B191","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-016-1021-2","article-title":"Safety and tolerability of an anti-CD19 monoclonal antibody, MEDI-551, in subjects with systemic sclerosis: a phase I, randomized, placebo-controlled, escalating single-dose study.","volume":"18","author":"Schiopu","year":"2016","journal-title":"Arthr Res Ther."},{"key":"B192","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1177\/1352458515620934","article-title":"Placebo-controlled study in neuromyelitis optica-Ethical and design considerations.","volume":"22","author":"Cree","year":"2016","journal-title":"Mul Scl (Houndmills Basingstoke England)."},{"key":"B193","doi-asserted-by":"publisher","first-page":"1474","DOI":"10.1136\/annrheumdis-2014-206016","article-title":"The proteasome inhibitior bortezomib depletes plasma cells and ameliorates clinical manifestations of refractory systemic lupus erythematosus.","volume":"74","author":"Alexander","year":"2015","journal-title":"Ann Rheum Dis."},{"key":"B194","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.4049\/jimmunol.1301555","article-title":"Proteasome inhibition with bortezomib depletes plasma cells and specific autoantibody production in primary thymic cell cultures from early-onset myasthenia gravis patients.","volume":"193","author":"Gomez","year":"2014","journal-title":"J Immunol."},{"key":"B195","first-page":"2638","article-title":"The proteasome inhibitor PS-341 in cancer therapy.","volume":"5","author":"Teicher","year":"1999","journal-title":"Clin Cancer Res."},{"key":"B196","first-page":"3071","article-title":"The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells.","volume":"61","author":"Hideshima","year":"2001","journal-title":"Cancer Res."},{"key":"B197","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1182\/bloodadvances.2016001412","article-title":"Bortezomib-based antibody depletion for refractory autoimmune hematological diseases.","volume":"1","author":"Ratnasingam","year":"2016","journal-title":"Blood Adv."},{"key":"B198","doi-asserted-by":"publisher","first-page":"2503","DOI":"10.4049\/jimmunol.1002539","article-title":"Proteasome inhibition with bortezomib depletes plasma cells and autoantibodies in experimental autoimmune myasthenia gravis.","volume":"186","author":"Gomez","year":"2011","journal-title":"J Immunol."},{"key":"B199","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.jneuroim.2017.08.005","article-title":"ONX-0914, a selective inhibitor of immunoproteasome, ameliorates experimental autoimmune myasthenia gravis by modulating humoral response.","volume":"311","author":"Liu","year":"2017","journal-title":"J Neuroimmunol."},{"key":"B200","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2018-024523","article-title":"Bortezomib in antibody-mediated autoimmune diseases (TAVAB): study protocol for a unicentric, non-randomised, non-placebo controlled trial.","volume":"9","author":"Kohler","year":"2019","journal-title":"BMJ Open."},{"key":"B201","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1080\/08830185.2016.1276903","article-title":"Targeting BAFF and APRIL in systemic lupus erythematosus and other antibody-associated diseases.","volume":"36","author":"Samy","year":"2017","journal-title":"Int Rev Immunol."},{"key":"B202","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1038\/nrrheum.2016.18","article-title":"The BAFFling effects of rituximab in lupus: danger ahead?","volume":"12","author":"Ehrenstein","year":"2016","journal-title":"Nat Rev Rheumatol."},{"key":"B203","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1038\/nri2572","article-title":"Cracking the BAFF code.","volume":"9","author":"Mackay","year":"2009","journal-title":"Nat Rev Immunol."},{"key":"B204","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/159632","article-title":"Serum soluble TACI, a BLyS receptor, is a powerful prognostic marker of outcome in chronic lymphocytic leukemia.","volume":"2014","author":"Kyrtsonis","year":"2014","journal-title":"Biomed Res Int."},{"key":"B205","doi-asserted-by":"publisher","first-page":"1618","DOI":"10.1093\/neuonc\/nox097","article-title":"Soluble TACI and soluble BCMA as biomarkers in primary central nervous system lymphoma.","volume":"19","author":"Thaler","year":"2017","journal-title":"Neuro Oncol."},{"key":"B206","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-019-0796-4","article-title":"APRIL and BAFF: novel biomarkers for central nervous system lymphoma.","volume":"12","author":"Mulazzani","year":"2019","journal-title":"J Hematol Oncol."},{"key":"B207","doi-asserted-by":"publisher","first-page":"1615","DOI":"10.1056\/NEJMoa1610528","article-title":"Overexpression of the cytokine BAFF and autoimmunity risk.","volume":"376","author":"Steri","year":"2017","journal-title":"New Engl J Med."},{"key":"B208","doi-asserted-by":"publisher","first-page":"3475","DOI":"10.1002\/art.11354","article-title":"B lymphocyte stimulator overexpression in patients with systemic lupus erythematosus: longitudinal observations.","volume":"48","author":"Stohl","year":"2003","journal-title":"Arthr Rheum."},{"key":"B209","doi-asserted-by":"publisher","first-page":"1833","DOI":"10.1136\/annrheumdis-2011-200831","article-title":"Effects of belimumab, a B lymphocyte stimulator-specific inhibitor, on disease activity across multiple organ domains in patients with systemic lupus erythematosus: combined results from two phase III trials.","volume":"71","author":"Manzi","year":"2012","journal-title":"Ann Rheum Dis."},{"key":"B210","doi-asserted-by":"publisher","DOI":"10.1212\/nxi.0000000000000077","article-title":"Characterization of B cells in muscle-specific kinase antibody myasthenia gravis.","volume":"2","author":"Guptill","year":"2015","journal-title":"Neurol Neuroimmunol Neuroinflam."},{"key":"B211","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.jneuroim.2008.05.010","article-title":"Serum BAFF expression in patients with myasthenia gravis.","volume":"199","author":"Kim","year":"2008","journal-title":"J Neuroimmunol."},{"key":"B212","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.1002\/mus.25162","article-title":"B-cell-activating factor is elevated in serum of patients with myasthenia gravis.","volume":"54","author":"Kang","year":"2016","journal-title":"Muscle Nerve."},{"key":"B213","doi-asserted-by":"publisher","first-page":"e1425","DOI":"10.1212\/WNL.0000000000005323","article-title":"Randomized study of adjunctive belimumab in participants with generalized myasthenia gravis.","volume":"90","author":"Hewett","year":"2018","journal-title":"Neurology."},{"key":"B214","doi-asserted-by":"publisher","first-page":"1464","DOI":"10.1002\/art.22603","article-title":"BAFF-modulated repopulation of B lymphocytes in the blood and salivary glands of rituximab-treated patients with Sjogren\u2019s syndrome.","volume":"56","author":"Pers","year":"2007","journal-title":"Arthr Rheum."},{"key":"B215","doi-asserted-by":"publisher","first-page":"2275","DOI":"10.1182\/blood-2010-10-307819","article-title":"Recovery of B-cell homeostasis after rituximab in chronic graft-versus-host disease.","volume":"117","author":"Sarantopoulos","year":"2011","journal-title":"Blood."},{"key":"B216","doi-asserted-by":"publisher","first-page":"2006","DOI":"10.1136\/annrheumdis-2013-205067","article-title":"Efficacy and safety of atacicept for prevention of flares in patients with moderate-to-severe systemic lupus erythematosus (SLE): 52-week data (APRIL-SLE randomised trial).","volume":"74","author":"Isenberg","year":"2015","journal-title":"Ann Rheum Dis."},{"key":"B217","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1002\/art.40360","article-title":"Efficacy and safety of atacicept in patients with systemic lupus erythematosus: results of a twenty-four-week, multicenter, randomized, double-blind, placebo-controlled, parallel-arm, phase IIb study.","volume":"70","author":"Merrill","year":"2018","journal-title":"Arthr Rheumatol."},{"key":"B218","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1517\/14712590903033919","article-title":"Atacicept, a novel B cell-targeting biological therapy for the treatment of rheumatoid arthritis.","volume":"9","author":"Bracewell","year":"2009","journal-title":"Exp Opin Biol Therapy."},{"key":"B219","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1177\/1756285610371146","article-title":"Atacicept: targeting B cells in multiple sclerosis.","volume":"3","author":"Hartung","year":"2010","journal-title":"Ther Adv Neurol Disord."},{"key":"B220","doi-asserted-by":"publisher","first-page":"1585","DOI":"10.1182\/blood.2019000050","article-title":"gamma-Secretase inhibition increases efficacy of BCMA-specific chimeric antigen receptor T cells in multiple myeloma.","volume":"134","author":"Pont","year":"2019","journal-title":"Blood."},{"key":"B221","first-page":"1017","article-title":"Eculizumab (Alexion).","volume":"2002","author":"Kaplan","year":"2000","journal-title":"Curr Opin Investigat Drugs (London, England)."},{"key":"B222","doi-asserted-by":"publisher","first-page":"2559","DOI":"10.1182\/blood-2005-02-0564","article-title":"Sustained response and long-term safety of eculizumab in paroxysmal nocturnal hemoglobinuria.","volume":"106","author":"Hill","year":"2005","journal-title":"Blood."},{"key":"B223","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1056\/NEJMoa031688","article-title":"Effect of eculizumab on hemolysis and transfusion requirements in patients with paroxysmal nocturnal hemoglobinuria.","volume":"350","author":"Hillmen","year":"2004","journal-title":"New Engl J Med."},{"key":"B224","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1053\/j.ajkd.2015.12.034","article-title":"Terminal complement inhibitor eculizumab in adult patients with atypical hemolytic uremic syndrome: a single-arm, open-label trial.","volume":"68","author":"Fakhouri","year":"2016","journal-title":"Am J Kidney Dis."},{"key":"B225","doi-asserted-by":"publisher","DOI":"10.1186\/s12882-019-1314-1","article-title":"Outcomes in patients with atypical hemolytic uremic syndrome treated with eculizumab in a long-term observational study.","volume":"20","author":"Menne","year":"2019","journal-title":"BMC Nephrol."},{"key":"B226","doi-asserted-by":"publisher","first-page":"2169","DOI":"10.1056\/NEJMoa1208981","article-title":"Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome.","volume":"368","author":"Legendre","year":"2013","journal-title":"New Engl J Med."},{"key":"B227","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1016\/s1474-4422(13)70076-0","article-title":"Eculizumab in AQP4-IgG-positive relapsing neuromyelitis optica spectrum disorders: an open-label pilot study.","volume":"12","author":"Pittock","year":"2013","journal-title":"Lancet Neurol."},{"key":"B228","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1056\/NEJMoa1900866","article-title":"Eculizumab in aquaporin-4-positive neuromyelitis optica spectrum disorder.","volume":"381","author":"Pittock","year":"2019","journal-title":"New Engl J Med."},{"key":"B229","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1002\/mus.23839","article-title":"A randomized, double-blind, placebo-controlled phase II study of eculizumab in patients with refractory generalized myasthenia gravis.","volume":"48","author":"Howard","year":"2013","journal-title":"Muscle Nerve."},{"key":"B230","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1002\/mus.25529","article-title":"QMG and MG-ADL correlations: Study of eculizumab treatment of myasthenia gravis.","volume":"56","author":"Howard","year":"2017","journal-title":"Muscle Nerve."},{"key":"B231","doi-asserted-by":"publisher","first-page":"2247","DOI":"10.1007\/s11136-019-02148-2","article-title":"Eculizumab improves fatigue in refractory generalized myasthenia gravis.","volume":"28","author":"Andersen","year":"2019","journal-title":"Qual Life Res."},{"key":"B232","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1016\/S1474-4422(17)30369-1","article-title":"Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study.","volume":"16","author":"Howard","year":"2017","journal-title":"Lancet Neurol."},{"key":"B233","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1007\/s40265-019-1065-0","article-title":"Therapies directed against B-cells and downstream effectors in generalized autoimmune myasthenia gravis: current status.","volume":"79","author":"Beecher","year":"2019","journal-title":"Drugs."},{"key":"B234","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1038\/nri2155","article-title":"FcRn: the neonatal Fc receptor comes of age.","volume":"7","author":"Roopenian","year":"2007","journal-title":"Nat Rev Immunol."},{"key":"B235","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2019.102366","article-title":"Next-generation Fc receptor-targeting biologics for autoimmune diseases.","volume":"18","author":"Zuercher","year":"2019","journal-title":"Autoimmun Rev."},{"key":"B236","doi-asserted-by":"publisher","first-page":"e2661","DOI":"10.1212\/WNL.0000000000007600","article-title":"Randomized phase 2 study of FcRn antagonist efgartigimod in generalized myasthenia gravis.","volume":"92","author":"Howard","year":"2019","journal-title":"Neurology."},{"key":"B237","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1002\/cpt.1276","article-title":"M281, an anti-FcRn antibody: pharmacodynamics, pharmacokinetics, and safety across the full range of IgG reduction in a first-in-human study.","volume":"105","author":"Ling","year":"2019","journal-title":"Clin Pharmacol Ther."}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fimmu.2020.00776\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T14:42:05Z","timestamp":1696171325000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fimmu.2020.00776\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,27]]},"references-count":237,"alternative-id":["10.3389\/fimmu.2020.00776"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2020.00776","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5,27]]},"article-number":"776"}}